Progressive Supranuclear Palsy (PSP) Treatment Guide

Progressive Supranuclear Palsy (PSP) Treatment Guide

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Progressive Supranuclear Palsy (PSP) Treatment Guide</th>
</tr>
<tr>
<td class="label">Medication</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>Dopamine precursor</td>
</tr>
<tr>
<td class="label">Amantadine</td>
<td>NMDA antagonist + dopamine release</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>D2/D3 agonist</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>D1/D2 agonist</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line Treatment</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Sertraline 50-200 mg/day</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate 5-20 mg/day</td>
</tr>
<tr>
<td class="label">Pseudobulbar affect</td>
<td>Dextromethorphan/quinidine (Nuedexta)</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Insomnia</td>
<td>Sleep hygiene + melatonin 3-5 mg</td>
</tr>
<tr>
<td class="label">REM sleep behavior disorder</td>
<td>Melatonin 3-12 mg at bedtime</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105685)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Bepran

Progressive Supranuclear Palsy (PSP) Treatment Guide

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Progressive Supranuclear Palsy (PSP) Treatment Guide</th>
</tr>
<tr>
<td class="label">Medication</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>Dopamine precursor</td>
</tr>
<tr>
<td class="label">Amantadine</td>
<td>NMDA antagonist + dopamine release</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>D2/D3 agonist</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>D1/D2 agonist</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line Treatment</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Sertraline 50-200 mg/day</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate 5-20 mg/day</td>
</tr>
<tr>
<td class="label">Pseudobulbar affect</td>
<td>Dextromethorphan/quinidine (Nuedexta)</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Insomnia</td>
<td>Sleep hygiene + melatonin 3-5 mg</td>
</tr>
<tr>
<td class="label">REM sleep behavior disorder</td>
<td>Melatonin 3-12 mg at bedtime</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105685)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Bepranemab (UCB0107)</td>
<td>UCB Pharma</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Senolytics (D+Q)</td>
<td>54/80</td>
</tr>
<tr>
<td class="label">NAD+ Precursors</td>
<td>53/80</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>53/80</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>53/80</td>
</tr>
<tr>
<td class="label">Methylene Blue</td>
<td>50/80</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>48/80</td>
</tr>
<tr>
<td class="label">Omega-3 DHA/EPA</td>
<td>48/80</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>40/80</td>
</tr>
<tr>
<td class="label">Team Member</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Movement disorder neurologist</td>
<td>Diagnosis, pharmacotherapy, clinical trial enrollment</td>
</tr>
<tr>
<td class="label">Physical therapist</td>
<td>Gait, balance, exercise program</td>
</tr>
<tr>
<td class="label">Occupational therapist</td>
<td>ADL adaptation, home safety, assistive devices</td>
</tr>
<tr>
<td class="label">Speech-language pathologist</td>
<td>Voice therapy, swallowing assessment, AAC</td>
</tr>
<tr>
<td class="label">Neuropsychologist</td>
<td>Cognitive assessment, behavioral strategies</td>
</tr>
<tr>
<td class="label">Social worker</td>
<td>Care coordination, financial planning, support resources</td>
</tr>
<tr>
<td class="label">Palliative care specialist</td>
<td>Symptom management, advance directives, end-of-life planning</td>
</tr>
<tr>
<td class="label">Dietitian/nutritionist</td>
<td>Weight monitoring, diet modification, PEG timing</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Assessment Tool</td>
</tr>
<tr>
<td class="label">Motor</td>
<td>PSP Rating Scale (PSPRS), Timed Up and Go</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>MoCA, Frontal Assessment Battery</td>
</tr>
<tr>
<td class="label">Falls</td>
<td>Fall calendar, injurious fall tracking</td>
</tr>
<tr>
<td class="label">Dysphagia</td>
<td>VFSS, weight tracking</td>
</tr>
<tr>
<td class="label">Mood</td>
<td>GDS, NPI</td>
</tr>
<tr>
<td class="label">Quality of life</td>
<td>PSP-QoL, PDQ-39</td>
</tr>
</table>

Progressive Supranuclear Palsy (PSP) is a progressive 4R tauopathy for which no FDA-approved disease-modifying therapies currently exist[@boxer2017]. This page provides a comprehensive treatment guide covering symptomatic pharmacotherapy, emerging disease-modifying approaches, and multidisciplinary management strategies for patients with PSP.

PSP, first described by Steele, Richardson, and Olszewski in 1964, is characterized by the accumulation of abnormal tau protein in the basal ganglia, brainstem, and cerebellar structures[@steele1964]. The classic Richardson's syndrome (PSP-RS) presents with vertical supranuclear gaze palsy, early postural instability with falls, and frontal cognitive dysfunction. Variant phenotypes include PSP-Parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP-PAGF), and corticobasal syndrome (CBS)[@litvan1996].

Treatment of PSP requires a multimodal approach combining:

Pathway / Interaction Diagram

Symptomatic Pharmacotherapy

Dopaminergic Agents

Levodopa remains the first-line pharmacological trial for motor symptoms in PSP, though efficacy is limited compared to Parkinson's disease[@steele1964]. Approximately 20-30% of patients, particularly those with PSP-P phenotype, show modest transient benefit.

Levodopa Trial Protocol: Initiate at 25/100 mg three times daily, titrate to maximum tolerated dose (typically 600-1000 mg/day of levodopa) over 4-6 weeks. Assess response using UPDRS motor scores. If no objective improvement after adequate trial, discontinue to avoid adverse effects.

Amantadine Use: Consider amantadine 100-200 mg twice daily for patients with prominent akinesia, rigidity, or gait freezing[@chen2019]. Side effects include confusion, hallucinations, peripheral edema, and livedo reticularis. Use cautiously in elderly patients.

Botulinum Toxin for Dystonia

Botulinum toxin injections are first-line for focal dystonia symptoms in PSP[@scelzo2003][@parks2021]:

Retrocollis (neck extension dystonia):

• Target muscles: splenius capitis, semispinalis capitis, trapezius
• Dose: OnabotulinumtoxinA 50-200 units per session
• Interval: Every 3-4 months
• Evidence: Moderate - significant improvement in neck posture and pain

• Target muscles: orbicularis oculi (pre-tarsal and pre-septal)
• Dose: OnabotulinumtoxinA 20-50 units per eye
• Interval: Every 3-4 months
• Evidence: Strong - first-line treatment

• Approach: Targeted pretarsal orbicularis injections
• Dose: Lower doses than blepharospasm (5-15 units)
• Often combined with ptosis/crutch glasses

• Target: Parotid and submandibular glands
• Dose: OnabotulinumtoxinA 30-50 units per gland
• Evidence: Moderate - significant reduction in drooling

• EMG-guided targeting of affected muscles
• Dose varies by muscle group and severity

Neuropsychiatric Symptom Management

Neuropsychiatric disturbances are common in PSP and significantly impact quality of life[@golbe2014]:

Apathy in PSP: Apathy is particularly common and often undertreated. It may be difficult to distinguish from depression. Methylphenidate requires monitoring for cardiac side effects. Modafinil may be better tolerated in some patients.

Pseudobulbar Affect: The combination of dextromethorphan/quinidine (Nuedexta) is the only FDA-approved treatment for pseudobulbar affect. Quinidine is a CYP2D6 inhibitor - check for drug interactions.

Cognitive Symptom Management

Cognitive impairment, particularly frontal/executive dysfunction, is a core feature of PSP[@lees2012]. Cholinergic deficits in the pedunculopontine nucleus (PPN) and cortical regions contribute to cognitive impairment:

• Rivastigmine: Small open-label trials suggest modest gait and attention benefit
• Donepezil: Case reports of mild cognitive improvement; may worsen parkinsonism
• Memantine: 10-20 mg/day may provide modest benefit via NMDA modulation
• Methylphenidate: May improve apathy-related cognitive dysfunction

Visual and Ocular Symptoms

Vertical supranuclear gaze palsy is the hallmark of PSP. Management strategies:

• Prism glasses: Base-down prisms to compensate for downgaze palsy during reading
• Lubricating eye drops: For exposure keratitis due to incomplete eyelid closure
• Eyelid weights: For eyelid-opening apraxia
• Speech/occupational therapy: Environmental modifications for visual limitations

Disease-Modifying Therapy Pipeline

Tau-Targeted Immunotherapies

Multiple monoclonal antibodies targeting tau are in clinical development for PSP[@shoeibi2019][@stamelou2021]:

The failure of tilavonemab and semorinemab in PSP trials highlights the challenge of treating an established neurodegenerative process. Future approaches may need to target earlier disease stages or different tau conformations.

Antisense Oligonucleotides (ASOs)

• BIIB080 (IONIS-MAPTRx): Anti-MAPT ASO that reduces total tau production; 50-60% CSF tau reduction demonstrated in Phase 1
• NIO752: Anti-tau ASO in development by Novartis

Tau Aggregation Inhibitors

• LMTM (TRx0237): Methylene blue derivative; failed Phase 3 in AD but LUCIDITY trial in bvFTD showed positive signal as monotherapy
• Gantenerumab: Anti-Aβ/tau bispecific antibody in development

GSK-3β Inhibitors

The glycogen synthase kinase-3β (GSK-3β) is a key kinase responsible for tau phosphorylation at multiple disease-relevant epitopes[@noble2005]:

• Tideglusib: GSK-3β inhibitor; TAUROS trial showed non-significant trend toward slowed progression; dose-limiting hepatotoxicity[@tolosa2014]
• Lithium: Natural GSK-3β inhibitor; requires careful monitoring (see Neuroprotective Strategies below)

Autophagy Enhancers

Agents that enhance autophagy-mediated tau clearance:

• Rapamycin (sirolimus): mTORC1 inhibitor; intermittent dosing protocols under investigation
• Trehalose: Natural disaccharide that enhances autophagy
• Valproic acid: HDAC inhibitor with autophagy-enhancing properties

Evidence-Based Neuroprotective Strategies

Tier 1: Highest-Evidence Interventions (Score ≥55/80)

These interventions have the strongest mechanistic rationale and clinical evidence:

Mediterranean/MIND Diet (Score: 64/80)
The highest-ranked intervention combines Mediterranean and DASH dietary patterns, emphasizing:

• Leafy greens (≥6 servings/week)
• Berries (≥2 servings/week)
• Nuts (≥5 servings/week)
• Olive oil as primary fat source
• Fish (≥1 serving/week)
• Whole grains
• Limited red meat, sweets, and fried foods

Structured Exercise (Score: 62/80)
Physical exercise is the single most impactful non-pharmacological intervention:

• 150+ minutes/week moderate aerobic activity
• 2x/week resistance training
• Daily balance exercises
• Stage-adapted protocols for advanced disease

Rasagiline (Score: 60/80)
MAO-B inhibitor with potential neuroprotective properties:

• Dose: 1 mg/day
• Mechanism: Propargylamine moiety activates anti-apoptotic pathways (Bcl-2 upregulation, PKC activation)
• Evidence: NNIPPS trial showed suggestive but non-significant trend toward slowed progression
• Note: Low tyramine interaction risk at 1 mg/day

• Protocol: 5-6 mg once weekly (intermittent dosing)
• Monitoring: Lipid panel, CBC, renal function
• Evidence: Geroscience longevity data; PEARL trial framework
• Contraindications: Active infection, severe liver disease

• Dose: R-enantiomer 600 mg/day with meals
• Mechanism: Scavenges reactive oxygen species, chelates metals, regenerates other antioxidants
• Evidence: Mixed results in clinical trials; strong preclinical data

• Dose: TUDCA 500 mg/day
• Mechanism: Reduce endoplasmic reticulum stress, improve mitochondrial function
• Evidence: AMX0035 (CENTAUR/PHOENIX trials) provides class evidence for neuroprotection in motor neuron disease

• Dose: 150-300 mg/day targeting serum levels of 0.3-0.6 mEq/L
• Monitoring: Thyroid function, renal function, lithium levels
• Contraindications: Thyroid disease, renal impairment, cardiac disease
• Evidence: Preclinical strong; clinical mixed[@noble2005]

• Dose: Wheat germ extract 1.2 mg/day spermidine equivalent
• Mechanism: EP300 inhibition and TFEB activation
• Evidence: SmartAge RCT demonstrated cognitive benefit in older adults

Tier 2: Moderate-Evidence Interventions (Score 45-54/80)

Critical Drug Interactions

• Methylene blue + SSRIs: Serotonin syndrome risk — contraindicated
• Lithium + NSAIDs: Increased lithium levels — monitor closely
• Rapamycin + CYP3A4 inhibitors: Increased rapamycin exposure
• Rasagiline + tyramine-rich foods: Hypertensive crisis (low risk at 1 mg/day)
• Amantadine + anticholinergics: Increased confusion risk

Non-Pharmacological Interventions

Physical Therapy

Physical therapy is the single most impactful intervention for functional outcomes in PSP:

Gait and Balance Training:

• Treadmill walking with body-weight support
• Rhythmic auditory cueing for freezing episodes
• Tai chi for balance improvement
• Standing perturbation training
• Dynamic weight shifting exercises

• Home safety assessment: grab bars, raised toilet seats, non-slip mats
• Hip protectors for high-risk patients
• Assistive devices: walkers, canes (adapted for vision impairment)

• Active and passive range-of-motion for retrocollis
• Isometric strengthening of cervical flexors
• Postural re-education

• Seated cycling for advanced stages
• Aquatic therapy to reduce fall risk
• Maintain cardiovascular fitness throughout disease course

Occupational Therapy

• Adaptive equipment: Weighted utensils, specialized writing aids
• Prism glasses: For downward gaze compensation during reading and meals
• Energy conservation: Task simplification techniques
• Home modification: Lighting, clutter reduction, bathroom safety
• Wheelchair/ scooter assessments: For advanced disease

Speech-Language Pathology

• Lee Silverman Voice Treatment (LSVT) LOUD: Gold-standard for hypophonia
• Swallowing assessment: Videofluoroscopic swallowing study (VFSS)
• Diet modification: Based on VFSS findings
• Augmentative and alternative communication (AAC): Eye-gaze devices for advanced dysarthria
• Swallowing techniques: Supraglottic swallow, effortful swallow

Cognitive Rehabilitation

• Cognitive reserve strategies: intellectually stimulating activities, social engagement, music therapy
• Compensatory strategies: external memory aids, structured routines
• Caregiver training: communication strategies, behavioral management

Dysphagia and Nutrition Management

Dysphagia develops in most PSP patients and is the leading cause of death via aspiration pneumonia[@mller2001]:

• Videofluoroscopic swallowing study (VFSS): Baseline assessment at diagnosis, repeated every 6-12 months
• Diet modification: Thickened liquids, soft solids as indicated by VFSS
• Swallowing techniques: Chin-tuck maneuver, supraglottic swallow technique
• PEG tube discussion: Initiate early as part of advance care planning; place before severe cachexia
• Weight monitoring: Monthly body mass tracking with nutritional supplementation as needed

Multidisciplinary Care Model

Optimal PSP management requires a coordinated team approach[@golbe2014]:

Biomarkers and Monitoring

Disease Progression Biomarkers

Tracking disease progression in PSP requires multimodal assessment[@respondek2019]:

• Neurofilament light chain (NfL): Elevated in CSF and blood; correlates with disease severity and progression rate
• Total tau and phosphorylated tau: CSF total tau elevated in PSP vs. controls; p-tau181 shows diagnostic promise
• Neurogranin: Synaptic marker elevated in PSP; reflects synaptic degeneration

Clinical Monitoring

Imaging Biomarkers

• MRI: Midbrain and superior cerebellar peduncle atrophy; "hummingbird sign" on midsagittal view
• PET/SPECT: Dopaminergic dysfunction on FP-CIT SPECT; reduced FDG uptake in frontal cortex and brainstem
• Tau PET: Emerging role in differential diagnosis and clinical trial enrollment

Clinical Trials and Future Directions

Active PSP Clinical Trials

The field of PSP therapeutics is actively evolving. Key resources for finding trials:

• [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=Progressive+Supranuclear+Palsy): Search for active PSP trials
• [CurePSP](https://www.psp.org/): Patient advocacy organization with trial information

Emerging Approaches

• CSF1R inhibitors: Target neuroinflammation via microglial modulation
• TREM2 agonists: Enhance microglial phagocytosis of pathological tau
• Gene therapy: AAV-based tau siRNA delivery
• Combination approaches: Multi-target therapies addressing tau, neuroinflammation, and neurodegeneration simultaneously

Precision Medicine

Future PSP treatment will likely incorporate:

• Genetic stratification: MAPT mutations, risk alleles
• Biomarker-guided patient selection: Tau PET, CSF biomarkers
• Phenotype-specific approaches: Different treatment strategies for PSP-RS vs. PSP-P vs. CBS

Patient Resources and Support

Organizations

• [CurePSP](https://www.psp.org/): Primary patient advocacy for PSP, CBS, and related disorders
• [The PSP Association (UK)](https://pspassociation.org.uk/): UK-based support organization
• [NINDS PSP Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Progressive-Supranuclear-Palsy-Information-Page): NIH resource

Practical Resources

• Advance care planning: Early discussion of directives given predictable progression
• Driving assessment: Typically discontinued within 1-2 years due to gaze palsy and falls
• Caregiver support: Respite services, support groups, financial assistance programs

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Disease overview
• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [CBS/PSP Genetic Architecture](/mechanisms/cbs-psp-genetic-architecture)
• [Cortisol-Tau Pathway](/mechanisms/cortisol-tau-pathway)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Related tauopathy
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
• [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan)
• [CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
• [The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;
• [Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052) &#x1f504;